Table 1

Prohibitin 3′ UTR C/T polymorphism genotype distribution among cases and controls

GroupCCCTTTTT or CT
N (%)P valueaN (%)P valuea (OR, 95% CI)N (%)P valuea (OR, 95% CI)N (%)P valuea (OR, 95% CI)
Controls170 (71.4)61 (25.6)7 (3.0)68 (28.6)
All breast cancer188 (64.6)1.0093 (32.0)0.1 (1.3, 0.9–2.0)10 (3.4)0.6 (1.3, 0.5–3.5)103 (35.4)0.1 (1.3, 0.9–2.0)
 Under 40 BrCab142 (68.3)1.0059 (28.4)0.5 (1.2, 0.7–1.7)7 (3.3)0.8 (1.2, 0.4–3.5)66 (31.7)0.5 (1.2, 0.7–1.7)
 Familialc BrCa123 (64.1)1.0065 (33.8)0.1 (1.5, 0.9–2.2)4 (2.1)0.7 (0.7, 0.2–2.8)69 (35.9)0.1 (1.4, 0.9–2.1)
  • a Fisher’s exact test (two-sided) for the relevant genotype using the CC genotype as reference. The ORs and 95% CIs are shown in brackets.

  • b BrCa, breast cancer.

  • c Family history is defined as two or more cases of breast cancer reported in first or second degree female relatives or bilateral breast cancer.